The effect of stem cells in repairing growth plate injury: a systematic review and meta-analysis

Xiao-long Xu
  Jingzhou Central Hospital

Sheng-jun Lu
  Jingzhou Central Hospital

Hong Pei
  Jingzhou Central Hospital

Shun-guang Chen
  Jingzhou Central Hospital

Quan-ming Liao (liaoqm211@163.com)
  Jingzhou Central Hospital

Systematic Review

**Keywords:** Growth plate, stem cell, regenerative therapy, preclinical evidence, meta-analysis

**Posted Date:** December 2nd, 2021

**DOI:** [https://doi.org/10.21203/rs.3.rs-1131432/v1](https://doi.org/10.21203/rs.3.rs-1131432/v1)

**License:** © This work is licensed under a Creative Commons Attribution 4.0 International License. [Read Full License](https://creativecommons.org/licenses/by/4.0/)
Abstract

Background: Multiple studies have focused on stem cell-based therapies for growth plate injury. However, the results are not consistent.

Objectives: This systematic review and meta-analysis were performed to evaluate the effects of stem cells on growth plate healing.

Methods: A detailed search of relevant studies was conducted in three databases including PubMed, Cochrane library, and Embase databases, using the following keywords: “growth plate” or “physis” AND “stem cell” from inception to November 10, 2021. The standard mean difference (SMD) and 95% confidence interval (CI) for each individual study were extracted from the original studies based on relevant data and pooled to obtain integrated estimates using random effects modeling.

Results: A total of 6 studies were identified. The results demonstrated that the angular deformity in the stem cell group was significantly lower than that in the control group at 4, 8, 12 and 16 weeks. The length discrepancy represented the degree of shortening deformity. In the stem cell group, the shortening deformity was milder than that of the control group at 16 weeks. Meanwhile, at 16 weeks after surgery, the higher histologic scores in the stem cell group indicated that stem cell can significantly improve the repair quality of growth plate.

Conclusions: This systematic review and meta-analysis confirmed that stem cell improved the rehabilitation of growth plate injury. However, larger-scale studies are needed to further support these findings.

1. Introduction

The growth plate, also named as physis, is a band of hyaline cartilage located at the proximal and distal ends of the long bones of children, and is responsible for bone lengthening until closure at skeletal maturity. The physis is prone to injury due to its fragile nature but has poor regenerative capacity due to its avascular state [1]. Injury to growth plate cartilage often results in an undesirable repair response mechanism at the site of injury, where ossification of the damaged tissue may lead to formation a bone bridge [2]. Establishment of a bone bridge across the growth plate can have serious consequences in growing children, and may lead to limb length discrepancy and angular deformity. In children, an estimated 15% of all fractures reportedly involve the growth plate and 15% of these lead to growth disturbance [3].

In early studies, free growth plate as a implanted material was transferred from the iliac apophysis into the growth plate defect zone in animal experiment to inhibit bony bar formation. The results indicate that the transplanted growth plate demonstrated different degrees of apoptosis [4]. Early experimental works showed that exvivo expanded chondrocytes can be successfully transplanted into a growth plate injury site and were able to form the growth plate-like columnar in rabbit [5, 6, 7, 8]. However, chondrocyte therapy for growth plate injury is controversial. In the other experiment, the researcher used a large animal (sheep) tibial growth plate injury model. He attempted transplanting chondrocytes directly into the growth plate injury site and did not produce any successful outcomes [9]. Hence, this highlights the unlikelihood of achieving successful growth plate cartilage regeneration with this chondrocyte transplantation approach. Moreover, using autologous chondrocytes clinically may be limited by the need to isolate cells from healthy pediatric cartilage tissue, thus creating secondary injury sites [4]. This has led to the investigation of alternative cell sources such as stem cells.

Stem cells are an attractive cell source for tissue engineering due to their availability and multipotent differentiation capacity, especially toward the bone and cartilage lineages [10, 11]. These cells include many types, such as bone marrow derived stem cells (BMSCs) [12, 13], adipose derived stem cells (ADSCs) [14, 15, 16], skeletal muscle derived stem cells [17, 18], umbilical cord blood derived mesenchymal stem cells (UCB-MSCs), periosteum derived stem cells [19, 20, 21], and synovial derived stem cells [22–24].
Stem cell therapy is an emerging therapeutic modality. The use of stem cells for growth plate repair have been studied by many researchers [22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33]. The main purpose of this meta-analysis was to summarize the best available evidence regarding the use of stem cells for the treatment of growth plate injury.

2. Materials And Methods

This study was performed according to the Preferred Reporting Items for Systematic Reviews and Meta Analyses (PRISMA) statement [34].

2.1. Search strategy

Three databases including PubMed, Cochrane library, and Embase databases have been searched for related studies from inception to November 10, 2021. To build up the literature, we selected the following terms: “growth plate”or “growth plate injury” or “physis” or “physis injury” or “physeal” and “stem cell” or “stem cells” or “progenitor cell”. The articles are limited to preclinical studies and published in English. Processes including online searching, reference lists screening, study selection, data extraction, and assessment of the risk of bias were performed by two investigators independently.

2.2. Study screening and eligibility criteria

The selection criteria for the studies were prespecified as follows: (1) the study applies stem cells for growth plate repair; (2) the study needs to use animal model; (3) a qualitative or quantitative outcome to determine if stem cells have provided improvement in growth plate repair, and (4) English language. Studies were excluded on the following criteria: (1) the study does not involve the use of any types of stem cell; (2) study protocols, letters, correspondence, and conference addressing; or (3) studies do not involve qualitative outcomes to determine if the stem cells have provided any improvement in growth plate repair.

2.3. Data extraction

The studies that did not meet the inclusion criteria were excluded after screening all the articles searched. The following details were recorded from the included articles: (1) the first author, year of publication, and country of studies; (2) the species and number of animals in the trial groups; (3) types and sources of stem cells; (4) intervention measures of treatment group and control group; and (5) evaluation of endpoint outcomes of interest: deformity angle, length discrepancy and histological scores. Standardized mean difference (SMD) and its 95% confidence interval (CI) were directly extracted from the articles or calculated according to the relevant data.

2.4. Assessment of the risk of bias

The quality assessment was performed by two research experts (SJ Lu and SG Chen) independently, and any disagreement was settled through discussion or judgement of a third investigator (QM Liao) when consensus could not be reached. The quality assessment was carried out using the modified Cochrane Collaboration tool to assess the risk of bias for randomized controlled trials. Bias is assessed as a judgment (high, low, or unclear) for individual elements from five domains (selection, performance, attrition, reporting, and other).

2.5. Statistical analysis

All analyses were implemented using the Review Manager V.5.3 software. Outcomes were continuous data and presented as standardized mean difference (SMD) with 95% confidence interval when the scales of data are inconsistent. The results of the meta-analysis are presented with forest diagram. The $I^2$ statistic was used to assess heterogeneity. When $I^2 > 50\%$, indicating that the included studies have significant heterogeneity. Explore the source of the heterogeneity when heterogeneity was obvious. Then sensitivity analyses were conducted by omitting studies one by one to assess the stability of the results and subgroup analyses were performed to address the source for heterogeneity.
3. Results

3.1. Selection Process

A total of 797 potential articles were obtained in the initial search through the database and references. Fig. 1 shows the stepwise selection procedure and reasons for exclusions. After excluding 11 reduplicated studies, the remaining 786 studies were further screened. After screening of the title and abstract of the remaining studies and a careful reading of the full text, 780 studies were excluded for the following reasons: (1) review article, (2) irrelevant studies, (3) inappropriate therapy method, (4) no available information, (5) growth factors are involved, and (6) comparison of different cells. Finally, 6 studies met the predefined inclusion criteria and therefore were included in the meta-analysis. All included 6 articles were reviewed thoroughly and the main characteristics of all these articles are summarized in Table 1.

3.3. Study characteristic and quality assessment

These studies were published in English. As for animal experiments, 5 studies used rabbits, 1 used pigs. Sample sizes of these studies ranged from 20 to 72. For the types of the stem cell, 3 studies used bone marrow mesenchymal stem cells, 2 used periosteum derived stem cells, and only 1 used synovial mesenchymal stem cells. For experimental model, 3 studies involved femoral growth plate defect model, 3 studies involved tibial growth plate defect model. For outcome measures, angle deformity and length discrepancy were used in all studies, histologic score in only two studies. All included studies were rated as high-quality in the risk of bias assessment.
Table 1

Characteristics of the included studies

| Author        | Year | Country      | Animal (number) | Stem cell | Tissue of origin | Experimental model                                                                 | Groups                                                                 | Outcome index |
|---------------|------|--------------|-----------------|-----------|------------------|-------------------------------------------------------------------------------------|------------------------------------------------------------------------|----------------|
| Chen[26]      | 2003 | Singapore    | New Zealand rabbits 36 | MSCs      | Periosteum       | Excised medial half of the proximal growth plate of the tibia                       | 1.Control 2.Periosteum flap 3.Agarose scaffold with MSCs              | 1.Varus angle 2.Length |
| Li[27]        | 2004 | Singapore    | New Zealand rabbits 72 | MSCs      | Periosteum       | Excised medial half of the proximal growth plate of the tibia                       | 1.Control 2.Chitin scaffold alone 3.Chitin scaffold with MSCs         | 1.Varus angle 2.Length |
| Plánka[28]    | 2007 | Czech Republic | New Zealand rabbits 20 | MSCs      | Bone marrow      | Excised lateral portion of the distal growth plate of the femur                    | 1.Control 2.MSCs alone 3.Gel scaffold with MSCs                         | 1.Valgus angle 2.Length |
| Plánka[30]    | 2009 | Czech Republic | Pigs 20           | MSCs      | Bone marrow      | Excised lateral portion of the distal growth plate of the femur                    | 1.Control 2.Collagen-chitosan scaffold with MSCs                     | 1.Valgus angle 2.Length |
| Kiyoshi[32]   | 2012 | Japan        | New Zealand rabbits 34 | MSCs      | Synovial membrane | Excised medial half of the proximal growth plate of the tibia                       | 1.Control 2.Bone wax 3.MSCs with extracellular matrix                | 1.Varus angle 2.Length |
| Azarpira[33]  | 2015 | Iran         | New Zealand rabbits 28 | MSCs      | Bone marrow      | Excised lateral portion of the distal growth plate of the femur                    | 1.Control 2.Chitosan scaffold 3.Chitosan scaffold with MSCs          | 1.Valgus angle 2.Length |

MSCs mesenchymal stem cells

3.3. The varus angle of tibial or valgus angle of femur

A total of 6 studies [26, 27, 28, 30, 32, 33] assessed the deformity angle of tibial or femur at 4, 8, 12, 16 weeks. The outcomes revealed that the deformity angle of tibial in the stem cell group was significantly lower than that in the control group at 4, 8, 16 weeks (SMD = -3.49, 95% CI: -5.54 to -1.43; SMD = -2.61, 95% CI: -5.19 to -0.03; SMD = -8.18, 95% CI: ...
-14.95 to -1.42, respectively) (Fig. 2). However, for the deformity angle of femur, the results indicated that the deformity angle at middle stage (12 weeks) showed no significant difference between the two groups (SMD = -0.88, 95% CI: -2.09 to 0.33). At longer follow-up (16 weeks), the deformity angle of femur in the stem cell group was significantly lower than that in the control group (SMD = -1.69, 95% CI: -2.55 to -0.83) (Fig. 3).

### 3.4. The difference in medial/lateral height of tibial plateau or the length of femur

The analysis of data from 4 studies [26, 27, 28, 30] evaluated the difference in medial/lateral height of tibial plateau or the length of femur. It demonstrated that the stem cell group had a significant smaller discrepancy in medial/lateral height of tibial plateau than control group at 8 and 16 weeks (SMD = -3.31, 95% CI: -5.28 to -1.34; SMD = -3.10, 95% CI: -4.73 to -1.48, respectively) (Fig. 4). Also, the difference about the femur length in the experimental group was significantly longer than that in the control group at 16 weeks (SMD = 0.45, 95% CI: 0.37 to 0.52) (Fig. 5).

### 3.5. The histological scores

Only 2 studies [32, 33] assessed the histological scores at 4, 8 and 12 weeks, confirming that there were no significant difference between the two groups in early and middle stages (SMD = 1.13, 95% CI: -0.14 to 2.4; SMD = 1.15, 95% CI: -0.18 to 2.48, respectively) (Fig. 6). While in later stage (12 weeks), the histological scores in the stem cell group was significantly higher than that in the control group (SMD = 1.45, 95% CI: 0.12 to 2.79) (Fig. 6).

### 4. Discussion

Due to accidents in sports and play, skeletal fracture are becoming more common in children, with up to 50% children experiencing a bone fracture [35]. It has been estimated that around 20% childhood bone fractures involve growth plate [36]. When such an injury happens, the ability of spontaneous repair is very limited, which results in significant orthopaedic problems such as limb length discrepancy and angular deformity [37, 38, 39]. In clinical practice, all of these available treatments so far are extremely invasive, time consuming, or may ineffective [39, 40]. Currently, finding a better treatment to promote growth plate repair have drawn researchers much interest.

Recently, biological therapies using stem cells to boost growth plate healing has become a hot researched topic. Mesenchymal stem cells are multipotent cells that are capable of differentiating into multiple cell types including osteoblasts, adipocytes, and chondrocytes. Many studies have focused on the application of mesenchymal stem cell treatments for growth plate. Our meta-analysis including 6 studies [26, 27, 28, 30, 32, 33] provided evidence that stem cells can improve the repair of the growth plate injury by radiological examination and histological analyse. Currently, stem cell therapy in combination with various scaffolds showed positive effects on growth plate healing. Stem cells have the ability to self-replicate through mitosis and reserve the capacity to differentiate into mature committed cells of various lineages [41].

The optimistic criteria for assessing growth plate repair are bone angular deformity, length discrepancy and histological assessment. Follow-up studies in the animal model were conducted at 4, 8, 12 and 16 weeks. Differences in angular deformity, limb length and histological score between therapy and control groups became significant beginning from 4, 8, 12 weeks respectively. This was observed to last up till 16 weeks post-implantation, after which the physis would close.

For the angular deformity, the varus angle of tibia in experimental groups was much milder than in control group from 4 weeks after surgery. However, the valgus angle of femur showed no significant difference between the two groups at 12 weeks after surgery. At 16 weeks postoperatively, the valgus deformity of femur was significantly improved. The discrepancy in medial/lateral height of tibial plateau or the length of femur were used to assess the therapeutic effectiveness of stem cells. The femur length in the experimental group was significantly longer than that in the control group at 16 weeks. Also, in the experimental, growth plate injury had little effect on tibial medial/lateral plateau height at 8,
16 weeks. Therefore, stem cells based therapy could relieve bone angular deformity and length discrepancy. Histological study for evaluation of regeneration of physis was also done in 2 studies. Histologic analyses at 4, 8 and 12 weeks after surgery were evaluated using two similar histologic grading scales. At 4 and 8 weeks after surgery, histologic scores for the repaired growth plate showed no significant difference between the two groups. However, the histologic scores of stem cell group at 12 weeks were significantly higher than that of control group. Taken together, stem cells were transferred into an experimental growth plate defect zone can promote growth plate healing, reduce bone bridge formation, prevent bone shortening and angular deformity.

For the clinical application of stem cells in patients, several major concerns need to be addressed. Currently, the most researched and applied stem cells types for growth plate repair were derived from bone marrow, periosteum, and synovial membrane. Previous studies have demonstrated that MSCs derived from various compartments possess different regenerative potentials [42]. Therefore, it is necessary to define the most practical way to promote the growth plate repair for clinical applications among all the available sources. Subsequently, another challenge for growth plate regeneration is to find the most appropriate carrier support systems (scaffolds) for MSC transplantation. The scaffolds should be biodegradable, biocompatible, promoting cell attachment, as well as allowing for tissue formation.

Nevertheless, this investigation still exist some potential limitations. First of all, although our analysis does prove the significant efficacy of stem cell-based treatments on growth plate, the heterogeneity between studies has to be mentioned. Therefore, we deal with the heterogeneity by random-effect model, standardized mean difference and subgroup analysis. Second, due to the small number of studies in the analysis, sensitivity analysis and publication bias were not conducted for the secondary outcomes. Third, the lack of some important data in several studies poses a barrier to more detailed subgroup analysis.

### Conclusion

In conclusion, the meta-analysis indicates that stem cell-based therapy was a promising method to repair growth plate injury. However, more preclinical studies are needed to further confirm the benefits and to produce the most suitable stem cells for future clinical study. Our further study will focus on the comparison between the improvements by different types of stem cells. And other impact factors such as scaffold can also be included in the comparison. Additional larger-scale and prospective studies are still needed to confirm our results.

### Abbreviations

| Abbreviation | Description |
|--------------|-------------|
| SMD          | standard mean difference |
| CI           | confidence interval |
| BMSCs        | bone mesenchymal stem cells |
| ADSCs        | adipose derived stem cells |
| UCB-MSCs     | umbilical cord blood derived mesenchymal stem cells |
| PRISMA       | Preferred Reporting Items for Systematic Reviews and Meta Analyses |

### Declarations
Acknowledgements

Not applicable.

Authors’ contributions

All authors contributed to all parts of the study. XLX, SJL, HP, SGC, and QML designed the study. XLX, SJL, and SGC collected the data and performed all analysis. XLX wrote the manuscript. QML supervised the work and revised the manuscript. All authors read and approved the final manuscript.

Funding

Not applicable.

Availability of data and materials

The data supporting the conclusions of this article are all online.

Ethics approval and consent to participate

Not applicable.

Consent for publication

All authors gave consent for publication.

Competing interests

The authors declare that they have no competing interests.

References

1. McCarty RC, Xian CJ, Grontos S, Zannettino AC, Foster BK. Application of autologous bone marrow derived mesenchymal stem cells to an ovine model of growth plate cartilage injury. Open Orthop J 2010; 10(4):204–210.

2. Xian CJ, Zhou FH, McCarty RC. Intramembranous ossification mechanism for bone bridge formation at the growth plate cartilage injury site. J Orthop Res 2004; 22(2):417-426.

3. Ecklund K, Jaramillo D. Imaging of growth disturbance in children. Radiol Clin North 2001; 39(4):823-841.

4. Shaw N, Erickson C. Regenerative Medicine Approaches for the Treatment of Pediatric Physeal Injuries. Tissue Eng Part B Rev 2018; 24(2):85-97.

5. Bentley G, Greer RB. Homotransplantation of isolated epiphyseal and articular cartilage chondrocytes into joint surfaces of rabbits. Nature 1971; 230(5293):385-388.

6. Lee EH, Chen F, Chan J. Treatment of growth arrest by transfer of cultured chondrocytes into physeal defects. Journal of Pediatric Orthopedics 1998; 18(2):155-160.

7. Jin XB, Luo ZJ, Wang J. Treatment of rabbit growth plate injuries with an autologous tissue-engineered composite. An experimental study. Cells Tissues Organs 2006; 183(2):62–67.
8. Li WC, Xu RJ, Xue YL, Huang JX. Treatment of growth plate injury with microencapsulated chondrocytes. Biotechnology and Bioprocess Engineering 2013; 18(2):655–662.

9. Hansen AL, Foster BK, Gibson GJ, Binns GF. Growth-plate chondrocyte cultures for reimplantation into growth-plate defects in sheep. Characterization of cultures. Clinical Orthopaedics and Related Research 1990; 256(2):286–298.

10. Hui J, Ouyang H, Hutmacher D, Goh J, Lee E. Mesenchymal stem cells in musculoskeletal tissue engineering: a review of recent advances in National University of Singapore. Ann Acad Med Singapore 2005; 34(2):206-212.

11. Barry FP, Murphy JM. Mesenchymal stem cells: clinical applications and biological characterization. Int J Biochem Cell Biol 2004; 36(4):568-584.

12. Caplan Al. Mesenchymal stem cells Journal of Orthopaedic Research. 1991; 9(5):641–650

13. Prockop DJ. Marrow stromal cells as stem cells for nonhematopoietic tissues. Science 1997; 276(5309):71–74.

14. Dragoo JL, Samimi B, Zhu M. Tissue-engineered cartilage and bone using stem cells from human infrapatellar fat pads. Journal of Bone and Joint Surgery 2003; 85(5):740–747.

15. Awad HA, Wickham MQ, Leddy HA, Gimble JM. Chondrogenic differentiation of adipose-derived adult stem cells in agarose, alginate, and gelatin scaffolds. Biomaterials 2004; 25(16):3211–3222.

16. Peterson B, Zhang J, Iglesias R. Healing of critically sized femoral defects, using genetically modified mesenchymal stem cells from human adipose tissue. Tissue Engineering 2005; 11(12):120–129.

17. Jankowski RJ, Deasy BM, Huard J. Muscle-derived stem cells. Gene Therapy 2002; 9(10):642–647.

18. Deasy BM, Jankowski RJ, Huard J. Muscle-derived stem cells: characterization and potential for cell-mediated therapy. Blood Cells, Molecules, and Diseases 2001; 27(5):924–933.

19. Nakamura K, Shirai T, Morishita S, Uchida S, Saeki Miura. p38 mitogen-activated protein kinase functionally contributes to chondrogenesis induced by growth/differentiation factor-5 in ATDC5 cells Experimental Cell Research. 1999; 250(2):351–363.

20. Fukumoto T, Sperling JW, Sanyal. A Combined effects of insulin-like growth factor-1 and transforming growth factor-beta1 on periosteal mesenchymal cells during chondrogenesis in vitro. Osteoarthritis and Cartilage 2003; 11(1):55–64.

21. Driscoll SW, Fitzsimmons JS. The role of periosteum in cartilage repair. Clinical Orthopaedics and Related Research 2001; 13(2):190–207.

22. Barry FP, Murphy JM. Mesenchymal stem cells: clinical applications and biological characterization. International Journal of Biochemistry and Cell Biology 2004; 36(4):568–584.

23. Bari CD, Accio DF, Vermeesch JR, Raymackers JM, Luyten FP. Skeletal muscle repair by adult human mesenchymal stem cells from synovial membrane. Journal of Cell Biology 2003; 160(6):909–918.

24. Tylzanowski P, Luyten FP. Multipotent mesenchymal stem cells from adult human synovial membrane. Arthritis and Rheumatism 2001; 44(8):1928–1942.

25. Li WC, Xu RJ, Huang JX, Bao X, Zhao B. Treatment of rabbit growth plate injuries with oriented ECM scaffold and autologous BMSCs. Sci Rep 2017; 7(7):440–451.
26. Chen F, Hui HP, Chan WK, Lee EH. Cultured Mesenchymal Stem Cell Transfers in the Treatment of Partial Growth Arrest. J Pediatr Orthop 2003; 23(4):425-429.

27. Li L, Hui HP, Goh CH, Fen Chen F, Lee EH. Chitin as a Scaffold for Mesenchymal Stem Cells Transfers in the Treatment of Partial Growth Arrest. J Pediatr Orthop 2004; 24(2):205-210

28. PLÁNKA L, NEÁS A, GÁL P, KECOVÁ H, FILOVÁ E. Prevention of Bone Bridge Formation Using Transplantation of the Autogenous Mesenchymal Stem Cells to Physeal Defects: An Experimental Study in Rabbits. ACTA VET 2007; 76(2):253–263.

29. Plánka L, Gal P, Kecova H, Klima J, Hlucilova J. Allogeneic and autogenous transplantations of MSCs in treatment of the physeal bone bridge in rabbits. BMC Biotechnol 2008; 12(8):70–79.

30. Plánka L, Necas A, Srnc R, Raiser P, Starý D, Jančář J. Use of Allogenic Stem Cells for the Prevention of Bone Bridge Formation in Miniature Pigs. Physiol Res 2009; 58(6):885-893

31. McCarty RC, Xian CJ, Gronthos S, Bruce KF. Application of Autologous Bone Marrow Derived Mesenchymal Stem Cells to an Ovine Model of Growth Plate Cartilage Injury. Open Orthop J 2010; 23(4):204-210.

32. Yoshida K, Higuchi C, Nakura A, Nakamura N. Treatment of Partial Growth Arrest Using an In Vitro-generated Scaffold-free Tissue engineered Construct Derived From Rabbit Synovial Mesenchymal Stem Cells. J Pediatr Orthop 2012; 32(3):314-321.

33. Azarpira MR, Shahcheraghi GH, Ayatollahi M, Geramizadeh B. Tissue engineering strategy using mesenchymal stem cell-based chitosan scafolds in growth plate surgery: A preliminary study in rabbits. Orthop Traumatol Surg Res 2015; 101(5):601-605.

34. Moher D, Liberati A, Tetzlaff J, Altman DG. Reprint preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Phys Ther 2009; 89(9):873-880.

35. Jones IE, Williams SM, Dow N. How many children remain fracture-free during growth? A longitudinal study of children and adolescents participating in the dunedin multidisciplinary health and development study. Osteoporosis International 2002; 13(12):990–995.

36. Mizuta T, Benson WM, Foster BK, Paterson DC. Statistical analysis of the incidence of physeal injuries. Journal of Pediatric Orthopaedics 1987; 7(5):518–523.

37. Ogden JA. Growth slowdown and arrest lines. Journal of Pediatric Orthopaedics 1984; 4(4): 518–523

38. Wattenbarger JM, Gruber HE, Phieffffer LS. Physeal fractures, part I: histologic features of bone, cartilage, and bar formation in a small animal model. Journal of Pediatric Orthopaedics 2002; 22(6):703–709.

39. Chung R, Foster BK, Xian CJ. Preclinical studies on mesenchymal stem cell-based therapy for growth plate cartilage injury repair. Stem Cells Int 2011; 5(7):125–135.

40. Xian CJ, Foster BK, et al. Repair of injured articular and growth plate cartilage using mesenchymal stem cells and chondrogenic gene therapy. Stem Cell Res Ther 2006; 1(2):213-229

41. Leo AJ, Grande DA, et al. Mesenchymal stem cells in tissue engineering. Cells Tissues Organs 2006; 183(3):112-122.

42. Kaviani M, Azarpira N, Aghdaie MH, Esfandiari E, Geramizadeh B, Nikeghbalian S. Comparison of human mesenchymal stem cells derived from various compartments of human adipose tissue and tunica adventitia layer of the
arteries subsequent to organ donation. Int J Organ Transplant Med 2019; 10(2):65-73.

**Figures**

**Figure 1**

Flow diagram for the selection of studies, with article search strategy results

| Study or Subgroup | Stem cell | Control | Std. Mean Difference |
|-------------------|-----------|---------|----------------------|
|                   | Mean      | SD      | Total                | Weight IV, Random, 95% CI |
| Kiyoshi 2012      | 9.1       | 3.44    | 7                    | 24 4.6 5 100.0%  -3.49 [-5.54, -1.43] |
| Subtotal (95% CI) | 7         |         | 5                    | 100.0%       | -3.49 [-5.54, -1.43] |

Heterogeneity: Not applicable

Test for overall effect: Z = 3.33 (P = 0.0009)

---

**Figure 2**

The forest plot: the effects of stem cells therapy for alleviating the varus deformity of tibial compared with controls.
Figure 3

The forest plot: the effects of stem cells therapy for alleviating the valgus deformity of femur compared with controls.
2.1.1 The discrepancy in medial and lateral height of tibia (cm) at 8 weeks

| Study or Subgroup | Stem cell Mean | Stem cell SD | Stem cell Total | Control Mean | Control SD | Control Total | Weight | IV. Random, 95% CI | IV. Random, 95% CI |
|-------------------|---------------|--------------|----------------|--------------|-----------|---------------|--------|-------------------|-------------------|
| Chen 2003         | 0.12          | 0.09         | 6              | 0.63         | 0.18      | 6             | 100.0% | -3.31 [-5.28, -1.34] |
| Subtotal (95% CI) |               |              | 6              |              |           |               | 100.0% | -3.31 [-5.28, -1.34] |

Heterogeneity: Not applicable

Test for overall effect: Z = 3.29 (P = 0.001)

2.1.2 The discrepancy in medial and lateral height of tibia (cm) at 16 weeks

| Study or Subgroup | Stem cell Mean | Stem cell SD | Stem cell Total | Control Mean | Control SD | Control Total | Weight | IV. Random, 95% CI | IV. Random, 95% CI |
|-------------------|---------------|--------------|----------------|--------------|-----------|---------------|--------|-------------------|-------------------|
| Chen 2003         | 0.08          | 0.07         | 6              | 1.38         | 0.38      | 6             | 29.4%  | -4.39 [-6.82, -1.97] |
| Li 2004           | 0.55          | 0.13         | 24             | 1.12         | 0.28      | 24            | 70.6%  | -2.57 [-3.35, -1.79] |
| Subtotal (95% CI) |               |              | 30             |              |           |               | 100.0% | -3.10 [-4.73, -1.48] |

Heterogeneity: Tau² = 0.82; Chi² = 1.97, df = 1 (P = 0.16); I² = 49%

Test for overall effect: Z = 3.74 (P = 0.0002)

Test for subarous differences: Chi² = 0.02, df = 1 (P = 0.881), I² = 0%

Figure 4

The forest plot: the effects of stem cells therapy for reducing the impact of growth plate injury on the height of the medial tibial plateau.
2.2.3 The femur length discrepancy (cm) at 16 weeks

| Study or Subgroup | Stem cell Mean | SD | Total | Control Mean | SD | Total | Weight | IV, Fixed, 95% CI | IV, Fixed, 95% CI |
|-------------------|----------------|----|--------|---------------|----|--------|--------|------------------|------------------|
| Plánka 2007       | 0.61           | 0.19 | 10     | 0.11          | 0.07 | 10     | 33.3%  | 0.50 [0.37, 0.63] |
| Plánka 2009       | 0.56           | 0.14 | 10     | 0.14          | 0.03 | 10     | 66.7%  | 0.42 [0.33, 0.51] |
| Subtotal (95% CI) | 20             |     | 20     | 100.0%        |     | 20     | 0.45   | [0.37, 0.52]     |

Heterogeneity: Chi² = 1.04, df = 1 (P = 0.31); I² = 4%
Test for overall effect: Z = 12.08 (P < 0.00001)

Total (95% CI) 20 20 100.0% 0.45 [0.37, 0.52]
Heterogeneity: Chi² = 1.04, df = 1 (P = 0.31); I² = 4%
Test for overall effect: Z = 12.08 (P < 0.00001)
Test for subrouxo differences: Not applicable

---

**Figure 5**
The forest plot: the effects of stem cells therapy for reducing the impact of growth plate injury on the length of femur.

**Figure 6**
The forest plot: the effects of stem cells therapy for improving the repair quality of growth plate.